FPT-SOFTWARE
1.2.2023 09:01:43 CET | Business Wire | Press release
FPT Software Europe, a subsidiary of FPT Software - leading technology and IT service provider headquartered in Vietnam, has recently announced its strategic partnership with Covestro AG (Covestro). As a leading global manufacturer of polymer materials, Covestro is included in DAX stock market index among major German companies trading on the Frankfurt Stock Exchange.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005414/en/
FPT Tower – FPT Corporation’s head quarter in Hanoi, Vietnam (Photo: Business Wire)
Entering a multi-year agreement with Covestro, FPT Software Europe is leveraging its in-depth experience, comprehensive services and best-shore model to support the DAX-listed group in the migration of 290 applications to the Amazon Web Services (AWS) cloud platform, thereby accelerating its digital transformation journey.
Starting signal for the next generation of IT infrastructure
Within the next few years, FPT Software Europe will accompany Covestro's entire transformation process. Starting with the assessment of customer requirements, the cloud experts analyze the chemical giant's legacy systems; design and implement solutions adapted to the AWS infrastructure. FPT Software Europe's core tasks in the migration process include refactoring legacy applications to preserve their functionality in the new ecosystem while leveraging the full potential of the new platform for the customer. By moving to AWS, Covestro AG is setting itself the goal of creating greater security for productive systems and business-critical workloads. Furthermore, by cloud migration, the company achieves additional benefits such as on-demand scalability of resources, increased productivity, and reduced capital and operating costs. With the move to the cloud, Covestro is laying the foundation for further digital transformation initiatives.
DAX company benefits from cloud migration expertise
FPT Software leverages its best-shore model, which is a mix of off shore, nearshore and onsite delivery to enable fast and cost-efficient processes to serve its customers like Covestro. As an AWS Advanced Partner with 600 highly qualified, certified AWS experts and around 20,000 highly trained IT specialists, FPT Software is able to implement the project in the shortest possible time and with the highest quality.
"As part of our promise to help Covestro accelerate its cloud migration, we have rapidly assembled project teams of cloud experts who work closely with the group's contacts on a day-to-day basis," said Le Hai, CEO of FPT Software Europe. "With the combined expertise of 600 certified AWS and 300 certified Microsoft experts, as well as thousands of other developers, FPT Software Europe is always ready to help European enterprises drive large-scale cloud projects and lay a solid foundation for broader digital transformation initiatives."
Through its partnership with FPT Software Europe, Covestro benefits from the comprehensive expertise of the Vietnamese IT service provider, which has already successfully implemented extensive cloud migration and digital transformation projects for major corporations like Schaeffler, RWE, Innogy and E.On.
FPT Software Europe and Covestro are discussing about further future joint projects in other areas such as managed services, cloud services with advanced application development and SAP implementation services.
About FPT Software Europe
FPT Software Europe, headquartered in Essen, Germany, is part of global technology and IT services provider FPT Software with 25,500 employees and revenue of more than $632.5 million. A pioneer in digital transformation, the company offers world-class services in Smart factory, Digital platforms, RPA (robotic process automation), Artificial Intelligence (AI), IoT (Internet of Thing), Data analytics, Mobility, Cloud, Managed services and Testing. FPT Software serves more than 1,000+ customers worldwide, 85 of which are Fortune Global 500 companies in the industries of Aerospace & Aviation, Manufacturing & Automotive, Banking Finance Insurance, Logistics & Transportation, Healthcare & Life Sciences, Retail, Utilities & Energy, and more. For more information, visit: www.fpt-europe.de.
About Covestro
Covestro is one of the world's leading manufacturers of high-quality plastics and their components. With its innovative products and processes, the company contributes to greater sustainability and quality of life in many areas. Covestro supplies global customers in key industries such as mobility, construction and housing, and electrical and electronics. In addition, Covestro's polymers are used in areas such as sports and leisure, cosmetics, healthcare and in the chemical industry itself.
The company is fully aligned with the circular economy and aims to become climate neutral by 2035 (Scope 1 and 2). In fiscal 2021, Covestro generated sales of €15.9 billion. As of the end of 2021, the company manufactures are presenting in 50 locations worldwide and employs around 17,900 people (full-time positions).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005414/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom